Biotechnology Synthetic Genomics Law In Russia.
1. Introduction
Synthetic genomics is an advanced branch of biotechnology involving the design, construction, modification and synthesis of genetic material, including DNA and RNA sequences, genomes and artificial biological systems.
It includes technologies such as:
Artificial genome construction.
Synthetic DNA and RNA production.
Genome assembly and modification.
CRISPR-based genetic engineering.
Synthetic microorganisms.
Artificial chromosomes.
Synthetic vaccines and biological products.
Gene circuits and engineered biological systems.
In Russia, synthetic genomics does not have a separate, comprehensive statute of its own. Instead, it is governed through several interconnected legal frameworks dealing with genetic engineering, environmental protection, public health, pharmaceutical regulation, scientific research, intellectual property and biological safety.
The principal legislation is Federal Law No. 86-FZ of 5 July 1996, On State Regulation in the Field of Genetic Engineering Activities.
An important distinction is that synthetic genomics involving microorganisms, plants or other organisms may fall within genetic-engineering regulation, whereas human genome research and therapeutic applications require additional consideration under medical, pharmaceutical and personal-data legislation.
cis-legislation.com+1
2. Constitutional and legislative foundations
The Russian Constitution provides the general legal foundations for biotechnology regulation.
Relevant constitutional provisions include:
Article 20: Right to life.
Article 21: Protection of human dignity.
Article 41: Right to health protection and medical assistance.
Article 42: Right to a favourable environment and environmental information.
Article 44: Protection of intellectual property and scientific creativity.
These provisions establish the constitutional background against which synthetic-genomics activities must be assessed.
Principal legislation
| Legislation | Relevance |
|---|---|
| Federal Law No. 86-FZ (1996) | Genetic engineering and genetically modified organisms |
| Federal Law No. 52-FZ (1998) | Sanitary and epidemiological welfare |
| Federal Law No. 7-FZ (2002) | Environmental protection |
| Federal Law No. 323-FZ (2011) | Public health and medical activities |
| Federal Law No. 61-FZ (2010) | Circulation of medicinal products |
| Federal Law No. 149-FZ (2006) | Information and information technologies |
| Federal Law No. 152-FZ (2006) | Personal data protection |
| Civil Code, Part IV | Patents and intellectual property |
| Federal Law No. 492-FZ (2020) | Biological safety |
These laws operate together rather than creating one unified synthetic-genomics licensing system.
3. Federal Law No. 86-FZ: The principal genetic-engineering legislation
Federal Law No. 86-FZ is the central statutory foundation.
It regulates activities involving genetic engineering, particularly where they affect environmental management, environmental protection, ecological safety and human health.
Its definition of genetic engineering covers techniques involving recombinant DNA and RNA, gene isolation, manipulation and introduction into other organisms.
Application to synthetic genomics:
Synthetic DNA inserted into microorganisms.
Artificially reconstructed microbial genomes.
Engineered agricultural organisms.
Genetically modified biological production systems.
Organisms developed using synthetic genetic sequences.
The important legal question is whether the particular technology and resulting organism fall within the statutory definitions. Merely synthesising a DNA sequence does not necessarily mean that every activity is subject to the same GMO registration requirements.
CIS Legislation+1
4. Regulation of synthetic genome research and laboratory activities
Synthetic genomics research can involve substantial biological risks. Russian law therefore distinguishes between controlled laboratory research and activities involving the release of genetically modified organisms into the environment.
A. Laboratory research
Research institutions conducting genetic-engineering activities must consider:
Laboratory biosafety standards.
Personnel training and qualifications.
Safe handling of biological materials.
Appropriate containment procedures.
Sanitary and epidemiological requirements.
Prevention of accidental environmental release.
Documentation and monitoring of research activities.
Research exemptions from GMO registration must not be interpreted as exemptions from all laboratory safety requirements.
B. Environmental release
The release of synthetic or genetically engineered organisms into the environment is subject to specific controls.
Relevant legislation includes:
Federal Law No. 86-FZ.
Federal Law No. 7-FZ on Environmental Protection.
Federal Law No. 149-FZ on Seed Production.
Government Resolution No. 35 of 18 January 2023.
Government Resolution No. 35 establishes the state-registration procedure and identifies exceptions, including organisms used for qualifying research and organisms not intended for environmental release.
CIS Legislation+1
C. Regulatory authorities
| Authority | Principal responsibility |
|---|---|
| Ministry of Health | Health and pharmaceutical regulatory matters |
| Rospotrebnadzor | Sanitary and food-safety supervision |
| Rosselkhoznadzor | Agricultural organisms, seeds and veterinary-related controls |
| Ministry of Natural Resources | Environmental policy and protection |
| Rospatent | Patent examination and intellectual property |
The applicable authority depends on the organism, research purpose and intended product.
5. Registration and approval of synthetic-genomics products
State registration is particularly important when genetically engineered organisms are intended for environmental release.
Under Government Resolution No. 35 of 2023, registration procedures cover genetically modified organisms and products obtained using or containing such organisms.
The framework includes:
Identification of the organism.
Identification of the genetic modification.
Assessment of the intended use.
Submission of the prescribed technical documentation.
Relevant safety and impact assessments.
Registration by the competent authority.
Inclusion in the relevant state register.
The registration period for an organism cannot exceed ten years under the specified rules.
Certain categories, including qualifying research organisms, organisms not intended for environmental release and certain medicines and medical devices, are excluded from this particular registration procedure. Their exclusion does not automatically remove other applicable regulatory obligations.
CIS Legislation+1
6. Human synthetic genomics and genome editing
Human synthetic genomics creates more complicated legal questions because genetic interventions may affect individual identity, reproductive rights, medical safety and future generations.
Russian legislation does not establish one comprehensive statutory regime specifically for synthetic human genomes.
Relevant legal areas include:
A. Somatic genome editing
Somatic editing concerns changes to non-reproductive cells. Its clinical application must be assessed under medical and pharmaceutical legislation, including Federal Law No. 323-FZ and Federal Law No. 61-FZ.
B. Germline genome editing
Germline editing involves changes that may be inherited by future generations. It raises additional questions concerning reproductive ethics, human dignity, medical safety and patent eligibility.
C. Human cloning
Federal Law No. 54-FZ of 20 May 2002 introduced a temporary prohibition on human cloning. Its statutory provisions must be considered separately from ordinary genome-editing research.
D. Genetic information
Genetic information can reveal highly sensitive information about individuals and their relatives. Its collection, processing, storage and transfer must therefore be examined under applicable genetic-data and personal-data legislation.
7. Genetic data protection and cross-border transfer
An important legislative development occurred in 2026.
Federal Law No. 43-FZ of 20 February 2026 amended Federal Law No. 86-FZ.
The amendments introduce express definitions concerning:
Human genetic data.
Genetic information obtained through molecular-genetic research.
Population genetic and immunological research.
Legal foundations for transferring human genetic data.
The amendments are scheduled to take effect on 1 September 2026 and are therefore relevant to the legal position on the date of this explanation.
CIS Legislation+1
For synthetic-genomics companies, this creates important compliance considerations.
For example, a Russian research institution collaborating with a foreign biotechnology company may need to assess:
Whether the information constitutes human genetic data.
Whether the research falls within population genetic research.
Whether the transfer is legally authorised.
Whether personal-data requirements are satisfied.
Whether confidentiality and security safeguards are adequate.
Whether additional restrictions apply to the recipient or destination.
Federal Law No. 152-FZ remains relevant to personal-data processing, alongside the specific genetic-data provisions.
8. Patent protection for synthetic genomics
Synthetic genomics can produce valuable intellectual property.
Examples include:
Artificial DNA sequences.
Synthetic microbial systems.
Engineered biological pathways.
Genetic constructs.
Genome-editing technologies.
Synthetic vaccines.
Industrial biological production methods.
Russian patent protection is principally governed by Part IV of the Civil Code.
Important patentability requirements
An invention generally must satisfy:
Novelty.
Inventive step.
Industrial applicability.
However, not every biological discovery or genetic sequence qualifies for patent protection.
There is also a distinction between patenting a technical method and claiming ownership over naturally occurring biological material.
Ethical limitations
Russian patent legislation restricts the patentability of certain inventions that conflict with public interests, humanity and morality.
Human germline modification presents particularly difficult patentability questions because the claimed invention may concern modification of the genetic integrity of reproductive cells.
This issue has been examined directly by the Russian Intellectual Property Rights Court.
9. Important Russian case laws
The following cases are particularly relevant to synthetic genomics. Two are direct judicial authorities concerning genome editing and GMO regulation.
Case 1. DNA-Technology v. Rospatent (2020)
Direct genome-editing precedent
Court: Intellectual Property Rights Court of the Russian Federation.
Case number: SIP-960/2019.
Decision date: 15 June 2020.
Subject: CRISPR/Cas9 editing of the human CCR5 gene.
Facts:
The applicant, Scientific Production Firm DNA-Technology, sought a patent for a method of editing the human CCR5 gene using CRISPR/Cas9.
The proposed method involved introducing the CCR5-delta32 deletion at an early embryonic stage, with the stated objective of increasing resistance to HIV.
Rospatent refused the patent application.
The applicant argued that modification at the zygote stage did not constitute modification of germline cells because specialised germline cells had not yet developed.
Legal issue:
Whether genetic modification of a human zygote could be treated as modification of the genetic integrity of human germline cells for the purpose of patent law.
Judgment:
The Intellectual Property Rights Court rejected the applicant's challenge and upheld Rospatent's refusal.
The Court reasoned that the genetic modification introduced at the zygote stage could remain in the developing individual's genome and be transmitted to descendants.
It applied Article 1349(4) of the Russian Civil Code, which excludes methods of modifying the genetic integrity of human germline cells from patentable subject matter.
Legal significance:
Germline genome modification faces a substantial patent-law barrier.
Early embryonic modification cannot avoid the prohibition merely because specialised germline cells have not yet developed.
Genetic technologies must be assessed according to their biological consequences, not simply the stage at which intervention occurs.
Ethical and public-interest considerations influence biotechnology patent examination.
This is one of the most important Russian judicial decisions for human synthetic genomics.
Документы ленты ПРАЙМ: ГАРАНТ.РУ+1
Case 2. Supreme Court of Russia – Unregistered genetically modified rapeseed (2023)
Direct GMO enforcement precedent
Court: Supreme Court of the Russian Federation.
Case number: 9-АД23-12-К1.
Decision date: 19 September 2023.
Subject: Use of unregistered genetically modified rapeseed.
Facts:
An agricultural company used genetically modified rapeseed containing the CP4 EPSPS genetic element on agricultural fields in the Nizhny Novgorod region.
The inspected fields covered approximately 394.92 hectares, 107.47 hectares and 47.37 hectares.
Regulatory authorities discovered the genetically modified material and found that the relevant registration requirements had not been satisfied.
Legal issue:
Whether the use of genetically modified organisms without the required registration constituted an administrative violation.
Judgment:
The Supreme Court upheld the earlier decisions finding the company administratively liable.
Legal significance:
Genetically modified organisms cannot be used contrary to applicable registration requirements.
Scientific or commercial use does not automatically establish regulatory compliance.
Laboratory identification of genetic material can be important evidence in enforcement proceedings.
Agricultural synthetic-genomics applications must comply with environmental and seed legislation.
Although this case concerned conventional genetic modification rather than a fully synthetic genome, its reasoning is relevant to synthetic-genomics products that fall within the GMO framework.
ГАРАНТ+1
Case 3. GMO rapeseed testing and administrative enforcement (2021)
Court: Arbitration Court of the Stavropol Territory.
Case number: A63-19388/2020.
Decision date: 4 October 2021.
Subject: Detection of genetically modified rapeseed.
Facts:
The proceedings concerned rapeseed samples in which authorities identified the genetically modified GT73 line and the CP4-EPSPS genetic sequence.
The dispute involved the evidentiary significance of laboratory testing and the quantity of detected genetically modified material.
The parties disagreed over whether the testing results established a regulatory violation.
Legal significance:
This dispute illustrates the importance of:
Reliable sampling procedures.
Laboratory accreditation and testing methods.
Genetic identification of modified organisms.
Evidence concerning the origin of biological samples.
Distinguishing the detection of GMO material from the legal question of whether its use is authorised.
It is a useful evidentiary example for synthetic-genomics litigation, although it is not a decision specifically about synthetic genomes.
sudact.ru
10. Biological safety and institutional accountability
Federal Law No. 492-FZ of 30 December 2020, On Biological Safety in the Russian Federation, provides another important part of the regulatory framework.
It establishes a system addressing biological threats, dangerous biological factors and biological-risk monitoring.
Its provisions address:
Protection of public health.
Environmental biological safety.
Monitoring biological risks.
Potentially dangerous biological facilities.
Prevention of biological accidents.
Government supervision and institutional responsibilities.
Liability for violations of biological-safety legislation.
For synthetic-genomics institutions, this legislation is relevant when research or industrial processes involve dangerous biological agents or potentially hazardous biological activities.
Consultant Plus+1
11. Liability for violations
Synthetic-genomics organisations may face different forms of legal liability depending on the nature of the violation.
| Liability | Examples |
|---|---|
| Administrative | Unauthorised GMO use or registration violations |
| Civil | Compensation for environmental or property damage |
| Criminal | Conduct satisfying the elements of an applicable criminal offence |
| Regulatory | Suspension, restrictions or withdrawal of relevant approvals |
| Intellectual property | Patent infringement or unlawful commercial exploitation |
| Data protection | Unlawful processing or transfer of protected genetic information |
Relevant legislation includes the Code of Administrative Offences, Criminal Code, Civil Code, Federal Law No. 7-FZ and Federal Law No. 492-FZ.
A company may also face contractual liability where its synthetic-genomics research or production breaches agreements concerning confidentiality, licensing, ownership of genetic constructs or research collaboration.
12. International and cross-border dimensions
Synthetic genomics is an international scientific activity. Russian researchers may collaborate with overseas universities, pharmaceutical companies, research institutions and biotechnology manufacturers.
Important international legal frameworks include:
Convention on Biological Diversity.
Cartagena Protocol on Biosafety.
TRIPS Agreement.
World Health Organization guidance on human genome editing.
Relevant Eurasian Economic Union pharmaceutical and technical regulations.
Their application depends on the treaty obligations binding on Russia and the subject matter of the activity. International recommendations should not be confused with directly enforceable Russian legislation.
Cross-border businesses must particularly consider:
Transfer of genetic data.
Import and export of biological materials.
Intellectual property ownership.
Research collaboration agreements.
Pharmaceutical product registration.
Biological safety and environmental requirements.
13. Major legal challenges
Several important challenges remain in Russian synthetic-genomics regulation.
A. Lack of a dedicated synthetic-genomics statute
The existing legislation was not originally designed for every modern synthetic-biology technology.
B. Classification of synthetic organisms
A major difficulty is determining whether a newly constructed biological system falls within the statutory definition of a genetically engineered organism.
C. Human germline modification
Article 1349(4) creates a clear patentability restriction for methods modifying the genetic integrity of human germline cells.
D. Scientific innovation versus public safety
Regulation must address the risks associated with new organisms while allowing lawful scientific research.
E. Genetic-data sovereignty and privacy
Genetic data can reveal information about individuals and biological relatives. Its transfer and commercial use therefore require appropriate safeguards.
F. Regulatory uncertainty
Technologies such as artificial chromosomes, synthetic microbial genomes and highly engineered biological systems may raise classification questions that existing legislation does not expressly resolve.
14. Practical compliance framework for synthetic-genomics companies
A Russian biotechnology company undertaking synthetic-genomics research should consider the following compliance sequence:
Technology classification
Determine whether the activity involves synthetic nucleic acids, genetic engineering, a genetically modified organism or human genetic research.
Regulatory assessment
Identify applicable provisions of Federal Laws No. 86-FZ, 492-FZ, 52-FZ and other relevant legislation.
Laboratory compliance
Establish suitable biosafety, personnel-training and biological-material handling procedures.
Registration assessment
Determine whether the organism or resulting product requires state registration.
Intellectual property examination
Assess patentability, ownership, licensing and ethical exclusions.
Genetic-data protection
Establish lawful collection, processing, storage and transfer arrangements.
Continuous monitoring
Maintain documentation, regulatory records and procedures for responding to safety incidents.
15. Conclusion
Biotechnology Synthetic Genomics Law in Russia is an emerging and fragmented area of biotechnology regulation rather than a fully independent legislative discipline.
Federal Law No. 86-FZ provides the principal genetic-engineering framework, while Federal Law No. 492-FZ addresses biological safety. Environmental legislation, pharmaceutical regulation, personal-data protection and intellectual property law provide additional safeguards.
Two judicial decisions are particularly significant:
SIP-960/2019 (2020): Establishes the patent-law restriction concerning modification of human germline genetic integrity.
9-АД23-12-К1 (2023): Demonstrates judicial enforcement of GMO registration and permitted-use requirements.
The 2026 amendments introducing express provisions on human genetic data transfers are also important for the development of Russian synthetic-genomics governance.
The central legal challenge is balancing scientific innovation, protection of human genetic integrity, environmental safety, biological security and intellectual property rights.
16. Important legal references for academic research
| Legal authority | Relevant subject |
|---|---|
| Constitution of the Russian Federation | Human rights and environmental protection |
| Federal Law No. 86-FZ (1996) | Genetic engineering |
| Federal Law No. 54-FZ (2002) | Human cloning |
| Federal Law No. 7-FZ (2002) | Environmental protection |
| Federal Law No. 61-FZ (2010) | Medicinal products |
| Federal Law No. 323-FZ (2011) | Public health |
| Federal Law No. 492-FZ (2020) | Biological safety |
| Federal Law No. 643-FZ (2022) | Amendments to genetic-engineering regulation |
| Government Resolution No. 35 (2023) | GMO registration |
| Government Resolution No. 291 (2024) | Registration exceptions |
| Federal Law No. 43-FZ (2026) | Genetic-data provisions |
| Civil Code, Article 1349(4) | Germline patent exclusions |
| Case SIP-960/2019 (2020) | Human germline genome editing |
| Case 9-АД23-12-К1 (2023) | Unregistered genetically modified rapeseed |
| Case A63-19388/2020 (2021) | GMO testing and evidence |
Primary research sources:
Federal Law No. 86-FZ – Russian genetic-engineering legislation.
Federal Law No. 492-FZ – Biological Safety.
Government Resolution No. 35 – GMO registration.
SIP-960/2019 – Intellectual Property Rights Court decision.
Supreme Court decision No. 9-АД23-12-К1.
Federal Law No. 43-FZ of 2026 – Genetic-data amendments.
Academic note: The analysis distinguishes direct synthetic-genomics legislation from broader GMO and genome-editing precedents. The cited cases are relevant analogies and should not be described as judgments directly deciding the legality of complete synthetic-genome construction. For litigation or regulatory submissions, the current official Russian-language statutory text and complete judgments should be checked.

comments